This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Devices, systems and methods are provided for treating conditions of the heart, particularly the occurrence of arrhythmias, more particularly atrial fibrillation. Therapeutic pulsed electric field energy is delivered to portions the heart to provide tissue modification, particularly to the entrances to the pulmonary veins in the treatment of atrial fibrillation. Such tissue modification creates a lesion or series of lesions which act as a conduction block within the tissue to prevent the transmission of aberrant electrical signals. Cardiovascular lesion analysis systems and methods provide information related to the effectiveness of the treatment during the procedure so as to create an electrical blockade within the heart that will remain durable and effective long-term.

The wound assessing method and system provide a convenient, quantitative mechanism for diabetic foot ulcer assessment.

An apparatus for monitoring neural response and/or providing treatment includes an electrical stimulator configured to apply electrical stimulation, and one or more processors configured to analyze stimulation response. The one or more processors can be further configured to operate the electrical stimulator, adjust the electrical stimulation, and determine one or more wound characteristics based at least in part on at least one of the electrical stimulation or the stimulation response, e.g. a movement of a patient, a color absorption characteristic, or other physiological responses. An indication of the one or more wound characteristics can be provided.

An electrode can comprise carbon black and one of polydimethylsiloxane (PDMS) or PVA, wherein the carbon black has a weight of between 10% and 50% of a weight of the PDMS or PVA. The electrode can be suitable for bioelectronics. A pattern of hydrogel can be deposited on the electrode for providing adhesion to a subject. The electrode can be used in wound treatment and/or monitoring devices or in various other bioelectronics applications.